Esophageal cancer screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
*The predominant type of esophageal cancer in the United States is [[adenocarcinoma]]. | *The predominant type of esophageal cancer in the United States is [[adenocarcinoma]]. | ||
*Under current guidelines, random endoscopic [[Biopsy|biopsies]] are taken in all 4 quadrants with a high resolution [[Endoscopy|endoscope]]. | *Under current guidelines, random endoscopic [[Biopsy|biopsies]] are taken in all 4 quadrants with a high resolution [[Endoscopy|endoscope]]. | ||
*It should be noted that those who presented with adenocarcinoma demonstrated no prior [[Barrett's esophagus]] in 80 - 90% of the time. | *It should be noted that those who presented with adenocarcinoma demonstrated no prior [[Barrett's esophagus]] in 80 - 90% of the time. | ||
*Most dysplastic changes are found in white men that are older than 50 years of age. | *Most dysplastic changes are found in white men that are older than 50 years of age. | ||
| Line 18: | Line 17: | ||
===Squamous cell carcinoma screening=== | ===Squamous cell carcinoma screening=== | ||
*Since squamous cell carcinoma of the esophagus is prevalent | *Since squamous cell carcinoma of the esophagus is more prevalent in underdeveloped countries, there is no reliable data to suggest that screening programs are effective when implemented. | ||
*However, in China, esophageal cancer is the sixth most common cancer and the fourth most common cause of death from cancer. | *However, in China, esophageal cancer is the sixth most common cancer and the fourth most common cause of death from cancer. | ||
*A screening program in a high risk population was put into effect where those with mild to moderate dysplasia are examined via endoscopy every 3 years, whilst those with severe dysplasia were screened once per year. | *A screening program in a high risk population was put into effect where those with mild to moderate dysplasia are examined via endoscopy every 3 years, whilst those with severe dysplasia were screened once per year. | ||
*The patients were concomitantly treated with monoclonal antibodies for the next three years, and the incidence decreased by 57%. | *The patients were concomitantly treated with monoclonal antibodies for the next three years, and the incidence decreased by 57%. | ||
Revision as of 13:13, 18 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer screening On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer screening |
|
Risk calculators and risk factors for Esophageal cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Screening may be effective in reducing the incidence of esophageal cancer, especially in Barrett's esophagus-associated adenocarcinoma, however, not very cost effective.
Screening
Adenocarcinoma screening
- The predominant type of esophageal cancer in the United States is adenocarcinoma.
- Under current guidelines, random endoscopic biopsies are taken in all 4 quadrants with a high resolution endoscope.
- It should be noted that those who presented with adenocarcinoma demonstrated no prior Barrett's esophagus in 80 - 90% of the time.
- Most dysplastic changes are found in white men that are older than 50 years of age.
- One study surmised that the only cost-effective strategy was once in a lifetime screening of 50+ year old, white men with GERD, followed by surveillance of those with dysplasia only.[1]
Squamous cell carcinoma screening
- Since squamous cell carcinoma of the esophagus is more prevalent in underdeveloped countries, there is no reliable data to suggest that screening programs are effective when implemented.
- However, in China, esophageal cancer is the sixth most common cancer and the fourth most common cause of death from cancer.
- A screening program in a high risk population was put into effect where those with mild to moderate dysplasia are examined via endoscopy every 3 years, whilst those with severe dysplasia were screened once per year.
- The patients were concomitantly treated with monoclonal antibodies for the next three years, and the incidence decreased by 57%.
- These results demonstrated that the screening for esophageal squamous cell carcinoma is effective in the prevention of esophageal cancer.[2]
References
- ↑ Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á (2015). "Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries". World J. Gastroenterol. 21 (26): 7933–43. doi:10.3748/wjg.v21.i26.7933. PMC 4499337. PMID 26185366.
- ↑ Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP (1988). "[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (3): 161–6. PMID 3219974.